Cellerant Therapeutics, Inc. to Present Results of Phase 2 Clinical Trial of CLT-008 at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and European Hematology Association (EHA) 23rd Congress

SAN CARLOS, Calif.–(BUSINESS WIRE)–Cellerant Therapeutics, Inc., a clinical-stage company developing
innovative immunotherapies for hematologic malignancies and other
blood-related disorders, today announced that investigators from
Cellerant’s recently completed Phase 2 clinical trial of CLT-008
(romyelocel-L, human myeloid progenitor cells) will present key study
results at the American Society of Clinical Oncology (ASCO) 2018 Annual
Meeting in Chicago, June 1-5, 2018, and at the 23rd Congress
of the European Hematology Association (EHA) in Stockholm, June 14-17,
2018.

Cellerant is developing CLT-008, a universal, off-the-shelf cell therapy
intended to prevent infections during neutropenia. Neutropenia is a
serious side effect of myelosuppressive chemotherapy that leaves
patients at high risk of serious, potentially life-threatening
infections, leading to prolonged hospitalization and often reduced or
delayed treatment doses. The Company conducted a randomized, controlled
Phase 2 study of CLT-008 in patients newly diagnosed with acute myeloid
leukemia (AML) who received induction chemotherapy.

“AML patients who undergo induction chemotherapy suffer severe and
prolonged neutropenia, and the results from this study show
significantly reduced infections in the CLT-008 group relative to
control,” said Ram Mandalam, Ph.D., CEO of Cellerant Therapeutics. “This
product addresses a serious unmet need in AML patients. We are excited
to present the study results at these two important medical meetings,
and look forward to advancing CLT-008 to a Phase 3 study.”

Presentation details are as follows:

ASCO Abstract #7043: Abboud, et al., A randomized controlled open
label exploratory trial of CLT-008 myeloid progenitor cells (MPC) to
decrease infections during induction for AML. Poster discussion on June
4, 2018, 8:00-11:30am CDT. Presenting author: Farhad Ravandi, M.D.,
Janiece and Stephen A. Lasher Professor of Medicine, University of Texas
MD Anderson Cancer Center.

EHA Abstract #1405: Desai, et al., Decreased incidence of
infection, use of antibacterials and days in hospital after
administration of CLT-008 myeloid progenitor cells to subjects receiving
AML induction therapy: Phase 2 Study Results. Oral presentation on June
16, 2018, 4:45-5:00pm CEST. Presenting author: Pinkal Desai, M.D.,
M.P.H., Assistant Professor of Medicine, Weill Cornell Medicine, New
York.

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical-stage company developing innovative
cell- and antibody-based immunotherapies for hematologic malignancies
and other blood-related disorders. Cellerant’s CLT-008 (romyelocel-L) is
a universal cell therapy intended to prevent infections during
neutropenia. Neutropenia is a severe side effect of many chemotherapy
regimens, particularly for acute myeloid leukemia (AML) and other
hematologic malignancies, and is also a serious condition in acute
radiation syndrome. Cellerant has completed a randomized, controlled
Phase 2 clinical trial of CLT-008 in patients with AML which showed that
CLT-008 significantly reduces infections, use of antimicrobials and days
in hospital compared to control. Cellerant’s CLT-008 program has been
supported by federal funds from the Biomedical Advanced Research and
Development Authority (BARDA), Department of Health and Human Services,
under contract HHSO100201000051C. Cellerant is also developing a novel
antibody drug-conjugate (ADC) product, CLT030, to treat AML by
selectively targeting and killing leukemic stem and blast cells. For
more information, visit: www.cellerant.com

Contacts

Cellerant Therapeutics, Inc.
Rodney Young, 650-232-2122
Chief
Financial Officer
info@cellerant.com